GH Research GHRS
NASDAQ GHRS
$27.79 -0.13 (-0.47%)
As of: Sep 4, 2026 · 1:36 PM EDT

GH Research (GHRS) Consolidated Net Income (2020 - 2026)

GH Research (GHRS) posted quarterly Consolidated Net Income of -$14.3 million for Q4 2025, down 32.91% year-over-year from -$21.3 million in Q4 2024, and down 1.38% quarter-over-quarter from -$14.1 million in Q3 2025.

Analysis

GH Research (GHRS) Consolidated Net Income (2020 - 2026) Analysis & Trends

GH Research's Consolidated Net Income history runs 6 years deep, the most recent figure standing at -$14.3 million for Q4 2025.

  • In Q4 2025, Consolidated Net Income fell 32.91% year-over-year to -$14.3 million; the TTM figure through Dec 2025 stood at -$47.5 million (down 15.75% YoY), while the FY2025 annual figure was -$47.5 million, down 15.75% from the prior year.
  • Consolidated Net Income for Q4 2025 stood at -$14.3 million, down from -$14.1 million in the prior quarter.
  • The five-year high for Consolidated Net Income was -$1.4 million in Q1 2021, with the low at -$14.5 million in Q4 2022.
  • The 5-year median for Consolidated Net Income is -$8.9 million (2024), against an average of -$9.0 million.
  • The sharpest annual moves came in 2021 and 2023: Consolidated Net Income plunged 10304.44% in 2021, then jumped 40.86% in 2023.
  • GH Research's Consolidated Net Income stood at -$12.8 million in 2021, then slipped by 13.7% to -$14.5 million in 2022, then surged by 40.86% to -$8.6 million in 2023, then retreated by 25.17% to -$10.7 million in 2024, then plunged by 32.91% to -$14.3 million in 2025.
  • Business Quant data shows GHRS's Consolidated Net Income at -$14.3 million in Q4 2025, -$14.1 million in Q3 2025, and -$8.8 million in Q2 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Consol Net Inc. (Qtr)
1 Vertex Pharmaceuticals 139.31 Bn 131.46 Bn 2.84 Bn 1.10 Bn
2 Regeneron Pharmaceuticals 85.65 Bn 77.66 Bn 3.93 Bn 1.30 Bn
3 Argenx Se 63.46 Bn 58.27 Bn 1.37 Bn 601.00 Mn
4 Moderna 57.94 Bn 52.80 Bn 52.00 Mn -782.00 Mn
5 Revolution Medicines 44.05 Bn 44.05 Bn - -644.37 Mn
6 BeOne Medicines 39.96 Bn 34.86 Bn 1.53 Bn 237.01 Mn
7 Alnylam Pharmaceuticals 35.16 Bn 31.85 Bn 992.69 Mn 164.49 Mn
8 Royalty Pharma 28.44 Bn 27.60 Bn - 81.49 Mn
9 Insmed 27.32 Bn 26.16 Bn 358.27 Mn -13.27 Mn
10 GH Research 1.71 Bn 1.34 Bn - -15.15 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -15.15 Mn
Mar 31, 2026 -18.97 Mn
Dec 31, 2025 -14.14 Mn
Sep 30, 2025 -14.02 Mn
Jun 30, 2025 -9.29 Mn
Mar 31, 2025 -10.81 Mn
Dec 31, 2024 -8.80 Mn
Sep 30, 2024 -12.11 Mn
Jun 30, 2024 -10.38 Mn
Mar 31, 2024 -7.67 Mn
Dec 31, 2023 -11.27 Mn
Sep 30, 2023 -5.65 Mn
Jun 30, 2023 -7.73 Mn
Mar 31, 2023 -10.94 Mn
Dec 31, 2022 -16.59 Mn
Sep 30, 2022 -441,000.00
Jun 30, 2022 334,000.00
Mar 31, 2022 -5.76 Mn
Dec 31, 2021 -4.09 Mn
Sep 30, 2021 -1.84 Mn